Claims for Patent: 9,458,241

Summary for Patent: 9,458,241

Title:	Antibody induced cell membrane wounding
Abstract:	Compositions and methods for inducing cell membrane wounding, cell permeabilization and cell killing are provided. The composition comprises a polyvalent agent that binds to a highly expressed cell surface antigen present on the surface of a cell. Preferably, the cell surface antigen is associated with the cytoskeleton of the cell. A preferred polyvalent agent is an IgM, and enhanced cell wounding and killing can be provided by the addition of a crosslinking agent. At sublethal concentrations in vivo, the cell wounding antibodies permeabilize cells and dramatically enhance response to chemotherapeutic agents, even in patients refractory to the chemotherapeutic agents.
Inventor(s):	Bhat; Neelima M (Los Altos, CA), Bieber; Marcia M. (Los Altos, CA), Teng; Nelson N. H. (Hillsborough, CA), Sanders; Martin E. (Hillsborough, CA)
Assignee:	IGM BIOSCIENCES, INC. (Santa Clara, CA)
Application Number:	13/770,619
Patent Claims:	1. A method of treating a mammal suffering from a condition characterized by hyperproliferation of B cells, wherein said hyperproliferating B-cells are cancer cells, comprising administering a cell membrane-wounding VH4-34antibody that binds to the CDIM epitope on the surface of B cells, in combination with a second cytotoxic agent, wherein said cell membrane wounding VH4-34 antibody is administered at a dosage that was determined to cause membrane pores that allow the second agent to enter said hyperproliferating B-cells to synergistically reduce viability of said hyperproliferating B cells, wherein the VH4-34 antibody is an IgM. 2. A method of treating a mammal suffering from a condition characterized by hyperproliferation of B cells, wherein said hyperproliferating B-cells are cancer cells, comprising administering a cell membrane-wounding VH4-34antibody that binds to the CDIM epitope on the surface of B cells, in combination with a second agent, wherein said cell membrane wounding VH4-34 antibody is administered at a dosage that was determined to cause membrane pores that allow the second agent to enter said hyperproliferating B-cells to synergistically reduce viability of said hyperproliferating B cells, wherein said second agent is a cytotoxic agent that interferes with the polymerization or depolymerization of microtubules. 3. The method of claim 2, wherein the cytotoxic agent that interferes with the polymerization or depolymerization of microtubules is a taxane, vinca alkaloid or colchicine, or mixtures thereof. 4. The method of claim 3, wherein the vinca alkaloid is vinblastine, vincristine, vindesine, or vinorelbine, or mixtures thereof. 5. The method of claim 4, wherein the taxane is paclitaxel, or docetaxel, or mixtures thereof. 6. A method of treating a mammal suffering from a condition characterized by hyperproliferation of B cells, wherein said hyperproliferating B-cells are cancer cells, comprising administering a cell membrane-wounding VH4-34antibody that binds to the CDIM epitope on the surface of B cells, in combination with a second cytotoxic agent, wherein said cell membrane wounding VH4-34 antibody is administered at a dosage that was determined to cause membrane pores that allow the second agent to enter said hyperproliferating B-cells to synergistically reduce viability of said hyperproliferating B cells, wherein the second agent is a cytotoxic antibody. 7. The method of claim 6, wherein the antibody has specific binding for CD11a, CD19, CD20, CD21, CD22, CD25, CD34, CD37, CD38, CD40, CD45, CD52, CD80, CD 86, IL-4R, IL-6R, IL-8R, IL-13R, integrin (VLA4), BLYS receptor, cell surface idiotypic Ig, or mixtures thereof. 8. The method of claim 6, wherein the antibody is rituximab, or anti-CD52. 9. The method of claim 2, wherein the condition characterized by a hyperproliferation of B cells is lymphoid cancer. 10. The method of claim 9, wherein the lymphoid cancer is acute or chronic leukemia, or lymphoma, of B-cell origin. 11. The method of claim 10, wherein the lymphoid cancer is acute lymphocytic leukemia (ALL), non-Hodgkins lymphoma (NHL), Burkitt's lymphoma, B progenitor ALL, adult ALL, or chronic lymphocytic leukemia (CLL). 12. The method of claim 2, wherein the viability of hyperproliferating B cells is reduced to about 42 percent. 13. The method of claim 2, wherein the viability of hyperproliferating B cells is reduced to about 30 percent. 14. The method of claim 2, wherein said cell membrane wounding VH4-34 antibody is administered at a dosage of about 1.25 mg/kg bodyweight. 15. The method of claim 6, wherein the condition characterized by a hyperproliferation of B cells is lymphoid cancer. 16. The method of claim 15, wherein the lymphoid cancer is acute or chronic leukemia, or lymphoma, of B-cell origin. 17. The method of claim 16, wherein the lymphoid cancer is acute lymphocytic leukemia (ALL), non-Hodgkins lymphoma (NHL), Burkitt's lymphoma, B progenitor ALL, adult ALL, or chronic lymphocytic leukemia (CLL). 18. The method of claim 6, wherein the viability of hyperproliferating B cells is reduced to about 42 percent. 19. The method of claim 6, wherein the viability of hyperproliferating B cells is reduced to about 30 percent. 20. The method of claim 6, wherein said cell membrane wounding VH4-34 antibody is administered at a dosage of about 1.25 mg/kg bodyweight.

Details for Patent 9,458,241

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2024-11-05
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2024-11-05
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017		2024-11-05